panitumumab
2 clinical trials
2 products
22 abstracts
2 indications
1 target
Indication
Colorectal CancerIndication
Head and Neck CancerTarget
EGFR mutationAbstract
Acquired gene alteration patterns and post-progression survival: PARADIGM study analysis.Org: National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, Disaster Medical Center, Tokyo, Japan, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
FU/FA maintenance therapy with or without panitumumab (pmab) in RAS wild-type metastatic colorectal cancer (mCRC) (PanaMa, AIO KRK 0212): Updated efficacy analyses.Org: Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Klinik Dr. Hancken GmbH,
Abstract
Negative hyperselection and mechanisms of acquired resistance to first-line chemotherapy plus anti-EGFR in patients (pts) with pMMR RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): A translational analysis of the TRIPLETE trial.Org: Azienda Ospedaliera Universitaria Pisana, Veneto Institute of Oncology - IRCCS, San Bortolo General Hospital, CRO Aviano, Fondazione Poliambulanza,
Abstract
Early [18F]FDG PET/CT response evaluation after a single dose of anti-EGFR therapy as a predictive biomarker for treatment benefit in patients with advanced colorectal cancer.Org: Cancer Centre Amsterdam, Radboud Medical Center,
Abstract
Therapeutic implications of acquired high tumor mutational burden (TMB-H) after targeted therapy (TT) in metastatic colorectal cancer (mCRC).Org: Memorial Sloan Kettering Cancer Center,
Abstract
Sotorasib plus panitumumab for pre-treated non-small cell lung cancer with KRAS G12C mutation: A phase 1b study.Org: Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, University Hospital Saint-Luc, Brussels, Belgium, Hospital Clinic Barcelona, Barcelona, Spain, CHU de Québec-Université Laval, Québec, QC, Canada, University of Iowa Hospitals and Clinics, Iowa City, IA,
Abstract
Phase IB/II first line panitumumab, irinotecan, trifluridine/tipiracil in RAS wild-type patients with metastatic colorectal cancer: PIT study.Org: Lyell McEwin Hospital, The Queen Elizabeth Hospital and University of Adelaide,
Abstract
AGITG MONARCC: A randomized phase 2 study of panitumumab monotherapy and panitumumab (pan) plus 5 fluorouracil (FU) as first-line therapy for RAS and BRAF wild type metastatic colorectal cancer—A trial by the Australasian Gastro-Intestinal Trials Group (AGITG).Org: NHMRC Clinical Trial Centre, Shoalhaven District Memorial Hospital, Flinders Medical Centre, Australasian Gastro-Intestinal Trials Group, Sunshine Hospital,
Clinical trial
A Randomized Phase II Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
A Phase III Study of Standard Fractionation Radiotherapy With Concurrent High-Dose Cisplatin Versus Accelerated Fractionation Radiotherapy With Panitumumab in Patients With Locally Advanced Stage III and IV Squamous Cell Carcinoma of the Head and NeckStatus: Completed, Estimated PCD: 2015-05-16
Abstract
Efficacy of panitumumab in patients with left-sided disease, MSS/MSI-L, and RAS/BRAF WT: A biomarker study of the phase III PARADIGM trial.Org: Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, Division of Gastrointestinal Surgery, Kanagawa Cancer Center, Kanagawa, Japan, Research and Development Center for Medical Education, Department of Clinical Skills Education, Kitasato University School of Medicine, Sagamihara, Japan, Division of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center, Sapporo, Japan,
Abstract
Size-related heterogeneity of colorectal liver metastases (CRLM) in patients with advanced RAS wild-type metastatic colorectal cancer (mCRC) treated in the PanaMa trial: Implication for treatment decisions.Org: Department of Hematology, Oncology and Tumorimmunology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany, Charité– Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt- Universität Zu Berlin, Berlin, Germany, Charité– Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin and Humboldt-Universitaet Zu Berlin, Berlin, Germany, Klinikum Neuperlach/ Klinikum Harlaching, Department of Hematology, Oncology, and Palliative Care, Munich, Germany, Klinik Dr. Hancken GmbH, Department of Hematology, Oncology, and Palliative Care, Stade, Germany, Kliniken Maria Hilf GmbH, Moenchen-Gladbach, Germany, Oncological Practice UnterEms, Leer, Germany, University Medical Center Goettingen, Department of Gastroenterology, Gastrointestinal Oncology, and Endocrinology, Goettingen, Ge...,
Abstract
Intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): An update of survival/toxicity and preliminary results of genomic alterations from IMPROVE study.Org: Istituto Nazionale Tumori-IRCCS Fondazione G. Pascale, National Cancer Research Centre, Istituto Tumori “Giovanni Paolo II”, Istituto Nazionale Tumori Fondazione G. Pascale, AORN DEI Colli - Monaldi Hospital,
Abstract
Nipavect: Phase II study of niraparib and panitumumab in advanced RAS WT colorectal cancer.Org: Winship Cancer Institute of Emory University, Emory University, Atlanta, GA, USA, Emory University School of Medicine, Winship Cancer Institute, Emory University School of Medicine, Emory University Winship Cancer Institute,
Abstract
Impact of number and size of colorectal metastases (CRM) on survival in patients with RAS wild-type metastatic colorectal cancer treated within the PanaMa trial (AIO KRK 0212).Org: Department of Hematology, Oncology and Tumorimmunology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany, Charité– Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt- Universität Zu Berlin, Berlin, Germany, Charité– Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin and Humboldt-Universitaet Zu Berlin, Berlin, Germany, Klinikum Neuperlach/ Klinikum Harlaching, Department of Hematology, Oncology, and Palliative Care, Munich, Germany, Klinik Dr. Hancken GmbH, Department of Hematology, Oncology, an...,
Abstract
Upfront vs deferred monoclonal antibodies in metastatic colorectal cancer: A target trial emulation using the GEMCAD 14-01 prospective cohort.Org: Hospital Clínic Barcelona, Antwerp University Hospital, Hospital Univ. Miguel Servet, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Complejo Hospitalario Universitario Ourense,
Abstract
Incidence of hypomagnesemia in patients with HER2+ breast cancer treated with pertuzumab.Org: University of Florida College of Medicine Jacksonville, University of Florida/UF Health Cancer Center,
Abstract
Frequency of KRAS, NRAS, and BRAF mutations in colorectal cancer in an Argentinian population.Org: Medical Affairs Department, Merck S.A., Biomakers SA,
Abstract
A functional immuno-oncology (IO) assay to assess patient response to immunotherapeutics in metastatic disease.Org: Xilis, Inc., Xilis Inc., Xilis,
Abstract
Real-world data on incidence of acute adverse reactions (AARs) reported in clinical practice.Org: Medical Day Hospital Unit Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Medical Day Hospital Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Pharmacy Unit Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori-University of Milan,
Abstract
Utility of next generation sequencing (NGS) in advanced malignancies in a community hospital in an underserved area: A game changer?Org: Mercy Catholic Medical Center, Lansdowne, PA, Darby, PA, PainReform,
Abstract
The impact of anti-EGFR therapy when added to first-line standard platinum-gemcitabine chemotherapy in advanced biliary tract cancers: A meta-analysis of randomized studies.Org: LSUHSC-S, Overton Brooks VAMC,
Abstract
Efficacy of vemurafenib based regimens in colorectal cancer: A systematic review of clinical trials.Org: New York Medical College - Saint Michael's Medical Center, Saint Michael's Medical Center, St. Michael's Medical Ctr, Reg Cancer Ctr At St Michael's Medical Ctr,
Product
panitumumab or cetuximab